اتوموکستین (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "اتوموکستین" in Persian language version.

refsWebsite

Global rank Persian rank

15nih.gov

4^th place

5^th place

14web.archive.org

1^st place

14doi.org

2^nd place

3adhdlife.ir

low place

4,414^th place

2drugs.com

399^th place

104^th place

2archive.org

6^th place

9^th place

2worldcat.org

5^th place

12^th place

2fda.gov

447^th place

382^nd place

1medscape.com

719^th place

248^th place

1tga.gov.au

3,984^th place

1,143^rd place

1psychiatry.org

low place

3,523^rd place

1bmj.com

1,226^th place

869^th place

1aacap.org

low place

1australianprescriber.com

low place

aacap.org

Matthew Siegel, MD., Craig Erickson, MD., MS, Jean A. Frazier, MD., Toni Ferguson, Autism Society of America., Eric Goepfert, MD., Gagan Joshi, MD., Quentin Humberd, MD., Bryan H. King, MD., Amy Lutz, EASI Foundation: Ending Aggression and Self-Injury in the Developmentally Disabled., Louis Kraus, MD., Alice Mao, MD., Adelaide Robb, MD., Jeremy Veenstra-VanderWeele, MD, PhD., Paul Wang, MD, Autism SpeaksCarmen J. Head, MPH, CHES, Director, Research, Development, & WorkforceEve, Bender, Scientific Editor. (2016). Autism_Spectrum_Disorder_Parents_Medication_Guide (PDF) (به انگلیسی). Washington, DC: American Academy of Child and Adolescent Psychiatry. p. 13. Archived from the original (PDF) on 2017-04-11. Atomoxetine (Strattera) has also been researched in controlled studies for treatment of ADHD in children with autism, and showed some improvements, particularly for hyperactivity and impulsivity {{cite book}}: |last= has generic name (help)نگهداری یادکرد:نام‌های متعدد:فهرست نویسندگان (link)

adhdlife.ir

«مجله بیش فعالی ایران». بایگانی‌شده از اصلی در ۱۲ ژانویه ۲۰۲۱. دریافت‌شده در ۴ ژانویه ۲۰۲۱.
«قرص اتوموکستین». بایگانی‌شده از اصلی در ۳۰ ژانویه ۲۰۲۱. دریافت‌شده در ۲۸ دسامبر ۲۰۲۰.
«قرص اتوموکستین - مجله بیش فعالی ایران». بایگانی‌شده از اصلی در ۳۰ ژانویه ۲۰۲۱. دریافت‌شده در ۲۸ دسامبر ۲۰۲۰.

archive.org

The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. 2012. ISBN 978-0-470-97948-8.
Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW (November 2002). "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics". Journal of Clinical Pharmacology. 42 (11): 1219–27. doi:10.1177/009127002762491307. PMID 12412820.

australianprescriber.com

"Atomoxetine and suicidality in children and adolescents". Australian Prescriber. Vol. 36, no. 5. October 2013. p. 166. Archived from the original on 10 November 2013. Retrieved 10 November 2013.

bmj.com

ebmh.bmj.com

Ghuman JK, Hutchison SL (November 2014). "Atomoxetine is a second-line medication treatment option for ADHD". Evidence-Based Mental Health. 17 (4): 108. doi:10.1136/eb-2014-101805. PMID 25165169. Archived from the original on 8 March 2016. Retrieved 8 March 2016.

doi.org

Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ (April 2013). "A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability". Journal of Child and Adolescent Psychopharmacology. 23 (3): 179–93. doi:10.1089/cap.2012.0093. PMC 3696926. PMID 23560600.
Ghuman JK, Hutchison SL (November 2014). "Atomoxetine is a second-line medication treatment option for ADHD". Evidence-Based Mental Health. 17 (4): 108. doi:10.1136/eb-2014-101805. PMID 25165169. Archived from the original on 8 March 2016. Retrieved 8 March 2016.
Kooij, JJS (2013). Adult ADHD Diagnostic Assessment and Treatment. Springer London. doi:10.1007/978-1-4471-4138-9. ISBN 978-1-4471-4137-2.
Kooij, JJS (2013). Adult ADHD Diagnostic Assessment and Treatment. Springer London. doi:10.1007/978-1-4471-4138-9. ISBN 978-1-4471-4137-2.
Perugi G, Vannucchi G (2015). "The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder". Expert Opinion on Pharmacotherapy. 16 (14): 2193–204. doi:10.1517/14656566.2015.1079620. PMID 26364896.
Kaplan, Harold I.; Sadock, Benjamin J. (1989-04). "Synopsis of Psychiatry". International Clinical Psychopharmacology. 4 (2): 161. doi:10.1097/00004850-198904000-00007. ISSN 0268-1315. {{cite journal}}: Check date values in: |date= (help)
Kaplan, Harold I.; Sadock, Benjamin J. (1989-04). "Synopsis of Psychiatry". International Clinical Psychopharmacology. 4 (2): 161. doi:10.1097/00004850-198904000-00007. ISSN 0268-1315. {{cite journal}}: Check date values in: |date= (help)
Todor I, Popa A, Neag M, Muntean D, Bocsan C, Buzoianu A, Vlase L, Gheldiu AM, Briciu C (April–June 2016). "Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers". Journal of Pharmacy & Pharmaceutical Sciences. 19 (2): 198–207. doi:10.18433/j3h03r. PMID 27518170.
Kasi PM, Mounzer R, Gleeson GH (2011). "Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system". Case Reports in Medicine. 2011: 952584. doi:10.1155/2011/952584. PMC 3135225. PMID 21765848.
Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW (November 2002). "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics". Journal of Clinical Pharmacology. 42 (11): 1219–27. doi:10.1177/009127002762491307. PMID 12412820.
Scherer D, Hassel D, Bloehs R, Zitron E, von Löwenstern K, Seyler C, Thomas D, Konrad F, Bürgers HF, Seemann G, Rottbauer W, Katus HA, Karle CA, Scholz EP (January 2009). "Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents". British Journal of Pharmacology. 156 (2): 226–36. doi:10.1111/j.1476-5381.2008.00018.x. PMC 2697834. PMID 19154426.
Sauer JM, Ring BJ, Witcher JW (2005). "Clinical pharmacokinetics of atomoxetine". Clinical Pharmacokinetics. 44 (6): 571–90. doi:10.2165/00003088-200544060-00002. PMID 15910008.

dx.doi.org

Kaplan, Harold I.; Sadock, Benjamin J. (1989-04). "Synopsis of Psychiatry". International Clinical Psychopharmacology. 4 (2): 161. doi:10.1097/00004850-198904000-00007. ISSN 0268-1315. {{cite journal}}: Check date values in: |date= (help)
Kaplan, Harold I.; Sadock, Benjamin J. (1989-04). "Synopsis of Psychiatry". International Clinical Psychopharmacology. 4 (2): 161. doi:10.1097/00004850-198904000-00007. ISSN 0268-1315. {{cite journal}}: Check date values in: |date= (help)

drugs.com

"Atomoxetine Hydrochloride Monograph for Professionals". Drugs.com (به انگلیسی). American Society of Health-System Pharmacists. Archived from the original on 4 April 2019. Retrieved 22 March 2019.
"Atomoxetine Pregnancy and Breastfeeding Warnings". Drugs.com (به انگلیسی). Archived from the original on 22 March 2019. Retrieved 3 March 2019.

fda.gov

accessdata.fda.gov

"21-411 Strattera Clinical Pharmacology Biopharmaceutics Review Part 2" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 1 March 2017. Retrieved 6 August 2017.

fda.gov

"FDA approves first generic Strattera for the treatment of ADHD" (Press release). May 30, 2017. Archived from the original on 4 June 2017. Retrieved January 1, 2018.

medscape.com

reference.medscape.com

"atomoxetine (Rx) - Strattera". Medscape Reference. WebMD. Retrieved 10 November 2013.

nih.gov

pubmed.ncbi.nlm.nih.gov

Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ (April 2013). "A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability". Journal of Child and Adolescent Psychopharmacology. 23 (3): 179–93. doi:10.1089/cap.2012.0093. PMC 3696926. PMID 23560600.
Ghuman JK, Hutchison SL (November 2014). "Atomoxetine is a second-line medication treatment option for ADHD". Evidence-Based Mental Health. 17 (4): 108. doi:10.1136/eb-2014-101805. PMID 25165169. Archived from the original on 8 March 2016. Retrieved 8 March 2016.
Perugi G, Vannucchi G (2015). "The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder". Expert Opinion on Pharmacotherapy. 16 (14): 2193–204. doi:10.1517/14656566.2015.1079620. PMID 26364896.
Todor I, Popa A, Neag M, Muntean D, Bocsan C, Buzoianu A, Vlase L, Gheldiu AM, Briciu C (April–June 2016). "Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers". Journal of Pharmacy & Pharmaceutical Sciences. 19 (2): 198–207. doi:10.18433/j3h03r. PMID 27518170.
Kasi PM, Mounzer R, Gleeson GH (2011). "Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system". Case Reports in Medicine. 2011: 952584. doi:10.1155/2011/952584. PMC 3135225. PMID 21765848.
Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW (November 2002). "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics". Journal of Clinical Pharmacology. 42 (11): 1219–27. doi:10.1177/009127002762491307. PMID 12412820.
Scherer D, Hassel D, Bloehs R, Zitron E, von Löwenstern K, Seyler C, Thomas D, Konrad F, Bürgers HF, Seemann G, Rottbauer W, Katus HA, Karle CA, Scholz EP (January 2009). "Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents". British Journal of Pharmacology. 156 (2): 226–36. doi:10.1111/j.1476-5381.2008.00018.x. PMC 2697834. PMID 19154426.
Sauer JM, Ring BJ, Witcher JW (2005). "Clinical pharmacokinetics of atomoxetine". Clinical Pharmacokinetics. 44 (6): 571–90. doi:10.2165/00003088-200544060-00002. PMID 15910008.

ncbi.nlm.nih.gov

Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ (April 2013). "A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability". Journal of Child and Adolescent Psychopharmacology. 23 (3): 179–93. doi:10.1089/cap.2012.0093. PMC 3696926. PMID 23560600.
Kasi PM, Mounzer R, Gleeson GH (2011). "Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system". Case Reports in Medicine. 2011: 952584. doi:10.1155/2011/952584. PMC 3135225. PMID 21765848.
Scherer D, Hassel D, Bloehs R, Zitron E, von Löwenstern K, Seyler C, Thomas D, Konrad F, Bürgers HF, Seemann G, Rottbauer W, Katus HA, Karle CA, Scholz EP (January 2009). "Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents". British Journal of Pharmacology. 156 (2): 226–36. doi:10.1111/j.1476-5381.2008.00018.x. PMC 2697834. PMID 19154426.

dailymed.nlm.nih.gov

"ATOMOXETINE HYDROCHLORIDE capsule [Mylan Pharmaceuticals Inc.]". DailyMed. Mylan Pharmaceuticals Inc. October 2011. Retrieved 10 November 2013.
"Strattera (atomoxetine) Capsules for Oral Use". DailyMed.gov. Eli Lilly and Company. 29 January 2020. Archived from the original on 7 June 2018. Retrieved 26 February 2020.

nimh.nih.gov

"NIMH » Attention Deficit Hyperactivity Disorder". NIMH » Home. الگو:NIMH. Archived from the original on 2016-12-25. Retrieved 2018-07-21.{{cite web}}: نگهداری CS1: سایر موارد (link)
"NIMH » Mental Health Medications". NIMH » Home. Archived from the original on 6 April 2019. Retrieved 2019-05-17.

psychiatry.org

"Parent's Medication Guide: ADHD". American Psychiatric Association (Guidelines (Tertiary source)). American Psychiatric Association & American Academy of Child and Adolescent Psychiatry (AACAP). June 2013. Archived from the original on 2017-02-02. Retrieved 2017-01-01. Though not FDA-approved for combined treatment, atomoxetine (Strattera) is sometimes used in conjunction with stimulants as an off-label combination therapy.

tga.gov.au

ebs.tga.gov.au

"STRATTERA® (atomoxetine hydrochloride)". TGA eBusiness Services. Eli Lilly Australia Pty. Limited. 21 August 2013. Retrieved 10 November 2013.

web.archive.org

"Parent's Medication Guide: ADHD". American Psychiatric Association (Guidelines (Tertiary source)). American Psychiatric Association & American Academy of Child and Adolescent Psychiatry (AACAP). June 2013. Archived from the original on 2017-02-02. Retrieved 2017-01-01. Though not FDA-approved for combined treatment, atomoxetine (Strattera) is sometimes used in conjunction with stimulants as an off-label combination therapy.
"Atomoxetine Hydrochloride Monograph for Professionals". Drugs.com (به انگلیسی). American Society of Health-System Pharmacists. Archived from the original on 4 April 2019. Retrieved 22 March 2019.
"Atomoxetine Pregnancy and Breastfeeding Warnings". Drugs.com (به انگلیسی). Archived from the original on 22 March 2019. Retrieved 3 March 2019.
"Strattera (atomoxetine) Capsules for Oral Use". DailyMed.gov. Eli Lilly and Company. 29 January 2020. Archived from the original on 7 June 2018. Retrieved 26 February 2020.
«مجله بیش فعالی ایران». بایگانی‌شده از اصلی در ۱۲ ژانویه ۲۰۲۱. دریافت‌شده در ۴ ژانویه ۲۰۲۱.
Ghuman JK, Hutchison SL (November 2014). "Atomoxetine is a second-line medication treatment option for ADHD". Evidence-Based Mental Health. 17 (4): 108. doi:10.1136/eb-2014-101805. PMID 25165169. Archived from the original on 8 March 2016. Retrieved 8 March 2016.
"NIMH » Attention Deficit Hyperactivity Disorder". NIMH » Home. الگو:NIMH. Archived from the original on 2016-12-25. Retrieved 2018-07-21.{{cite web}}: نگهداری CS1: سایر موارد (link)
"NIMH » Mental Health Medications". NIMH » Home. Archived from the original on 6 April 2019. Retrieved 2019-05-17.
Matthew Siegel, MD., Craig Erickson, MD., MS, Jean A. Frazier, MD., Toni Ferguson, Autism Society of America., Eric Goepfert, MD., Gagan Joshi, MD., Quentin Humberd, MD., Bryan H. King, MD., Amy Lutz, EASI Foundation: Ending Aggression and Self-Injury in the Developmentally Disabled., Louis Kraus, MD., Alice Mao, MD., Adelaide Robb, MD., Jeremy Veenstra-VanderWeele, MD, PhD., Paul Wang, MD, Autism SpeaksCarmen J. Head, MPH, CHES, Director, Research, Development, & WorkforceEve, Bender, Scientific Editor. (2016). Autism_Spectrum_Disorder_Parents_Medication_Guide (PDF) (به انگلیسی). Washington, DC: American Academy of Child and Adolescent Psychiatry. p. 13. Archived from the original (PDF) on 2017-04-11. Atomoxetine (Strattera) has also been researched in controlled studies for treatment of ADHD in children with autism, and showed some improvements, particularly for hyperactivity and impulsivity {{cite book}}: |last= has generic name (help)نگهداری یادکرد:نام‌های متعدد:فهرست نویسندگان (link)
"Atomoxetine and suicidality in children and adolescents". Australian Prescriber. Vol. 36, no. 5. October 2013. p. 166. Archived from the original on 10 November 2013. Retrieved 10 November 2013.
"21-411 Strattera Clinical Pharmacology Biopharmaceutics Review Part 2" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 1 March 2017. Retrieved 6 August 2017.
«قرص اتوموکستین». بایگانی‌شده از اصلی در ۳۰ ژانویه ۲۰۲۱. دریافت‌شده در ۲۸ دسامبر ۲۰۲۰.
"FDA approves first generic Strattera for the treatment of ADHD" (Press release). May 30, 2017. Archived from the original on 4 June 2017. Retrieved January 1, 2018.
«قرص اتوموکستین - مجله بیش فعالی ایران». بایگانی‌شده از اصلی در ۳۰ ژانویه ۲۰۲۱. دریافت‌شده در ۲۸ دسامبر ۲۰۲۰.

worldcat.org

Kaplan, Harold I.; Sadock, Benjamin J. (1989-04). "Synopsis of Psychiatry". International Clinical Psychopharmacology. 4 (2): 161. doi:10.1097/00004850-198904000-00007. ISSN 0268-1315. {{cite journal}}: Check date values in: |date= (help)
Kaplan, Harold I.; Sadock, Benjamin J. (1989-04). "Synopsis of Psychiatry". International Clinical Psychopharmacology. 4 (2): 161. doi:10.1097/00004850-198904000-00007. ISSN 0268-1315. {{cite journal}}: Check date values in: |date= (help)